How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy?

References

• World Cancer Research Fund International, London. Worldwide cancer data. World Cancer Research Fund International. [cited 2023 Jun 15]. Available from: wcrf.org
   Google Scholar
• Malvezzi M, Santucci C, Boffetta P, et al. European cancer mortality predictions for the year 2023 with focus on lung cancer. Ann Oncol. 2023;34(4):410–419. doi: 10.1016/j.annonc.2023.01.010
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 CA cancer. J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   Google Scholar
• Registro Tumori Friuli Venezia Giulia. [cited 2023 Jul 3]. Available from: https://www.cro.sanita.fvg.it/export/sites/cro/it/ricercatori/documenti/registro-tumori-fvg-2020.pdf
   Google Scholar
• Waarts MR, Stonestrom AJ, Park YC, et al. Targeting mutations in cancer. J Clin Invest. 2022;132(8):e154943. doi: 10.1172/JCI154943
   PubMed Web of Science ®Google Scholar
• Sarkar C, Das B, Rawat VS, et al. Artificial intelligence and machine learning technology driven modern drug discovery and development. Int J Mol Sci. 2023;24(3):2026. doi: 10.3390/ijms24032026
   PubMed Web of Science ®Google Scholar
• Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–967.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu H, Ye Y, et al. Smart nanoparticles for cancer therapy. Sig Transduct Target Ther. 2023;8(1):418. doi: 10.1038/s41392-023-01642-x
   PubMed Web of Science ®Google Scholar
• Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29(3):489–98. doi: 10.1007/s10637-009-9376-8
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi: 10.1126/science.aar6711
   PubMed Web of Science ®Google Scholar
• Del Baldo G, Del Bufalo F, Pinacchio C, et al. The peculiar challenge of bringing CAR-T cells into the brain: perspectives in the clinical application to the treatment of pediatric central nervous system tumors. Front Immunol. 2023;14:1142597. doi: 10.3389/fimmu.2023.1142597
   PubMed Web of Science ®Google Scholar
• Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. doi: 10.1126/science.1258096
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551. doi: 10.1038/nature12796
   PubMed Web of Science ®Google Scholar
• Wang S, Tian Y, Wang M, et al. Advanced activity-based protein profiling application strategies for drug development. Front Pharmacol. 2018;9:353. doi: 10.3389/fphar.2018.00353
   PubMed Web of Science ®Google Scholar
• Brown KK, Hann MM, Lakdawala AS, et al. Approaches to target tractability assessment - a practical perspective. MedChemcomm. 2018;9(4):606–613. doi: 10.1039/C7MD00633K
   PubMed Web of Science ®Google Scholar
• Wang H, Guo M, Wei H, et al. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92. doi: 10.1038/s41392-023-01347-1
   PubMed Web of Science ®Google Scholar
• Vicente ATS, Salvador JAR. MDM2-based proteolysis-targeting chimeras (PROTACs): an innovative drug strategy for cancer treatment. Int J Mol Sci. 2022;23(19):11068. doi: 10.3390/ijms231911068
   PubMed Web of Science ®Google Scholar
• Childs-Disney JL, Yang X, Gibaut QMR, et al. Targeting RNA structures with small molecules. Nat Rev Drug Discov. 2022 10;21(10):736–762. doi: 10.1038/s41573-022-00521-4
   PubMed Web of Science ®Google Scholar
• Arghiani N, Shah K. Modulating microRnas in cancer: next-generation therapies. Cancer Biol Med. 2022;19:289–304. doi: 10.20892/j.issn.2095-3941.2021.0294
   Web of Science ®Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-Engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. doi: 10.1126/science.aba7365
   PubMed Web of Science ®Google Scholar
• Proietto M, Crippa M, Damiani C, et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front Oncol. 2023;13:1164535. doi: 10.3389/fonc.2023.1164535
   PubMed Web of Science ®Google Scholar
• Jung J, Heo YJ, Park S, et al. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer. 2023;11(4):e006454. doi: 10.1136/jitc-2022-006454
   PubMed Web of Science ®Google Scholar
• Watterson A, Coelho MA. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell Commun Signal. 2023;21(1):45. doi: 10.1186/s12964-023-01063-x
   PubMed Web of Science ®Google Scholar
• Marusyk A, Janiszewska M, Polyak K, et al. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell. 2020;37(4):471–484. doi: 10.1016/j.ccell.2020.03.007
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Fountzilas E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019. doi: 10.1016/j.ctrv.2020.102019
   PubMed Web of Science ®Google Scholar
• Stockley TL, Oza AM, Berman HK, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 2016;8(1):109. doi: 10.1186/s13073-016-0364-2
   PubMed Web of Science ®Google Scholar
• Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29(9):1895–1902. doi: 10.1093/annonc/mdy263
   PubMed Web of Science ®Google Scholar
• Andre F, Filleron T, Kamal M, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610(7931):343–348. doi: 10.1038/s41586-022-05068-3
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Ford JM, O’Dwyer PJ, et al. National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH). Clin Cancer Res. 2023;29(8):1412–1422. doi: 10.1158/1078-0432.CCR-22-3334
   PubMed Web of Science ®Google Scholar
• Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-Mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–4038. doi: 10.1200/JCO.2015.63.2497
   PubMed Web of Science ®Google Scholar
• Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, et al. Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022;28(7):1402–1411. doi: 10.1158/1078-0432.CCR-21-3752
   PubMed Web of Science ®Google Scholar
• Subramanian M, Wojtusciszyn A, Favre L, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. J Transl Med. 2020;18(1):472. doi: 10.1186/s12967-020-02658-5
   PubMed Web of Science ®Google Scholar
• Orzetti S, Tommasi F, Bertola A, et al. Genetic therapy and molecular targeted therapy in oncology: safety, pharmacovigilance, and perspectives for research and clinical practice. Int J Mol Sci. 2022;23(6):3012. doi: 10.3390/ijms23063012
   PubMed Web of Science ®Google Scholar
• Baldo P, Francescon S, Fornasier G, et al. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. Int J Clin Pharm. 2018;40(4):748–753. doi: 10.1007/s11096-018-0711-z
   PubMed Web of Science ®Google Scholar